Press Release | March 24, 2023 Thunder Bay, Ontario, Canada - July 25, 2022 – IGY Life Sciences and Immune Technologies Inc.(the "Company" or "IGY Life Sciences") is pleased to announce the closing of $12.8 million (CDN) in financing this week. This represents the largest single injection of funds into the Company since it [...]
Press Release | July 25, 2022 Thunder Bay, Ontario, Canada - July 25, 2022 – IGY Life Sciences and Immune Technologies Inc. (the "Company" or "IGY Life Sciences") is pleased to announce it has reached 94.8% purity of Muno-IgYTM, the Company’s branded nutraceutical IgY ingredient for targeting immune and gut health through supplementation of [...]
Media Feature IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever. Read Article (PDF)
Businesswire | June 8, 2020 THUNDER BAY, Ontario--(BUSINESS WIRE)--IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a [...]